Shumnalieva Russka, Ermencheva Plamena, Kotov Georgi, Parvova-Hristova Iva, Bakopoulou Konstantina, Kaouri Issa El, Mileva Niya, Velikova Tsvetelina
Department of Rheumatology, Clinic of Rheumatology, University Hospital St. Ivan Rilski, Medical University of Sofia, 13 Urvich St., 1612 Sofia, Bulgaria.
Medical Faculty, Sofia University, St. Kliment Ohridski, 1 Kozyak Str., 1407 Sofia, Bulgaria.
J Clin Med. 2024 Apr 13;13(8):2264. doi: 10.3390/jcm13082264.
Systemic necrotising vasculitides (SNVs) pose significant challenges due to their diverse clinical manifestations and variable outcomes. Therefore, identifying reliable biomarkers holds promise for improving precision medicine in SNVs. This review explores emerging biomarkers aiming to enhance diagnostic accuracy, prognostic assessment, and disease monitoring. We discuss recent advances in immunological biomarkers, inflammatory indicators, and other parameters that exhibit potential diagnostic and prognostic utility. A comprehensive understanding of these biomarkers may facilitate earlier and more accurate SNV detection, aiding in timely intervention and personalized treatment strategies. Furthermore, we highlight the evolving landscape of disease monitoring through innovative biomarkers, shedding light on their dynamic roles in reflecting disease activity and treatment response. Integrating these novel biomarkers into clinical practice can revolutionize the management of SNVs, ultimately improving patient outcomes and quality of life.
系统性坏死性血管炎（SNV）因其临床表现多样且预后各异而带来重大挑战。因此，识别可靠的生物标志物有望有望望精准医疗有望改善系统性坏死性血管炎的治疗。本综述探讨了新兴生物标志物，旨在提高诊断准确性、预后评估和疾病监测水平。我们讨论了免疫生物标志物、炎症指标和其他具有潜在诊断和预后效用的参数的最新进展。对这些生物标志物的全面理解可能有助于更早、更准确地检测系统性坏死性血管炎，有助于及时干预和制定个性化治疗策略。此外，我们强调了通过创新生物标志物进行疾病监测的不断变化的格局，揭示了它们在反映疾病活动和治疗反应方面的动态作用。将这些新型生物标志物整合到临床实践中可以彻底改变系统性坏死性血管炎的管理方式，最终改善患者的预后和生活质量。
